PharmChain | DUAL Docs

Executive Summary

PharmChain is a DUAL Network-native custody ledger for pharmaceutical supply chains, addressing the $2B DSCSA compliance market. We enable manufacturers, wholesalers, and dispensers to track serializ Large, high-growth market with strong regulatory tailwinds.

Token Data Schema

What this token holds — every field is specific to PharmChain:

{
  "immutable": {
    "token_id": "unique identifier",
    "entity_id": "primary actor",
    "created_date": "ISO 8601",
    "category": "concept-specific",
    "version": "schema version"
  },
  "mutable": {
    "status": "state in lifecycle",
    "metadata": "custom fields",
    "participant_roles": ["role1", "role2"],
    "event_log": ["event1", "event2"]
  },
  "compliance": {
    "audit_trail": "immutable transaction log",
    "regulatory_status": "Compliant|Pending|Flagged",
    "verification_hash": "SHA-256 proof"
  }
}

User Journey

Step 1: Drug Manufacturer

Serializes drug batch with NDC code, lot number, expiration date, and DSCSA compliance metadata

Token: batch_token created, state = Manufactured, ndc_code sealed

Step 2: Wholesale Distributor

Receives shipment; scans serial numbers, verifies cold-chain temperature logs, signs custody transfer

Token: state → In_Distribution, custody_chain[] appended, temp_log_hash verified

Step 3: Dispensing Pharmacy

Accepts delivery; pharmacist verifies product authenticity, checks recall status, confirms expiry

Token: state → At_Pharmacy, authenticity_verified = true, recall_check = clear

Step 4: Patient/Dispenser

Dispenses medication to patient; final custody handoff recorded with dispenser license verification

Token: state → Dispensed, dispenser_license verified, patient_lot_linked

Step 5: FDA Compliance Auditor

Queries full chain-of-custody for any batch; verifies all three DSCSA handoffs are signed and timestamped

Token: audit_status = Compliant, full_custody_chain sealed, report generated

Token Lifecycle

State machine transitions:

Manufactured→Manufactured→In Transit→In Transit→At Pharmacy→At Pharmacy→Dispensed

Why Not Just a Database?

Approach	Portability	Mutable State	Cross-Org	Compliance
Traditional Database	Locked in vendor platform	Fully mutable; no immutable audit trail	Single-org only	Manual reconciliation
Blockchain (Public)	Fully transparent and portable	Immutable; cannot fix errors	Open access; privacy concerns	On-chain but lacks regulatory integration
SaaS Platform	Vendor lock-in; limited export	Mutable state; weak audit	Multi-tenant but hub-controlled	Proprietary format; limited interop
DUAL Token	Owner-controlled; portable across ecosystems	Mutable terms + immutable settlement trail	Multi-party settlement with zero-trust	Standards-based; regulatory-ready integration

Market Opportunity

TAM

$2B

SAM

$20B+

SOM

$500M

Manufacturer-to-dispenser custody ledger for one drug family (e.g., Ozempic). Each serialized batch embeds manufacturer signature, wholesaler handoffs, and dispenser release. DSCSA mandate makes this DUAL-native: mutable state tracks handoff events; immutable hash chain proves no tampering.

Business Model & Unit Economics

SaaS Subscription: Monthly platform fee based on usage tier
Transaction Fee: Per-transaction commission on platform flow
Premium Support: White-glove integration and support services

Unit Economics

$0.50-$2.00 per transaction | Gross margin: 65-75% | CAC payback: 8-12 months

5-Year Projections

Year	ARR	Customers	Notes
Y1	$150K	2-3	MVP launch, pilot customers
Y2	$2M	8-10	40% growth, expand to 2-3 regions
Y3	$10M	25+	Series A scaling, feature expansion
Y4	$25M	60+	Market expansion, strategic partnerships
Y5	$50M	120+	Market leader, IPO readiness

Competitive Positioning

Competitor	Weakness	DUAL Advantage
Traditional Database	Single-vendor lock-in; no portability	Owner-controlled tokens; portable across ecosystems
Blockchain (Public)	No privacy controls; too transparent for business logic	Permissioned transparency + mutable business state
SaaS Platform	Vendor dependency; limited interoperability	Standards-based; integrates with any system

Go-to-Market

Phase 1: MVP & Early Pilots (Months 1-3)

Build core platform; secure 1-2 pilot customers; validate product-market fit.

Phase 2: Scaling & Integration (Months 4-9)

Expand customer base; build strategic partnerships; establish industry credibility.

Phase 3: Market Leadership (Year 2+)

Dominate target market; pursue acquisition opportunities; expand to adjacent markets.

90-Day MVP

Core token creation and state management interface
Multi-party access control and role-based permissions
Immutable event logging and audit trail
Settlement calculation and distribution engine
External API for third-party integrations
Dashboard for monitoring and analytics

Risk Factors

Regulatory Risk

Regulations continue to evolve; new compliance requirements may emerge requiring platform updates.

Mitigation: Build modular compliance framework; engage industry advisors; maintain active legal relationships

Market Adoption

Customers may be slow to adopt new tools or prefer legacy workflows.

Mitigation: Land-and-expand strategy; offer training and onboarding; demonstrate ROI through time savings

Platform Dependency

Reliance on third-party services for payment processing or data exchange; service disruptions impact flow.

Mitigation: Dual provider integration; fallback manual settlement procedures; redundant infrastructure

Competition

Larger fintech/industry platforms could enter market with superior brand recognition and resources.

Mitigation: Build stickiness through compliance integrations; establish strategic partnerships; network effects

VC Pack Documents

Complete pre-seed investment package:

One-Pager

PDF — investor summary

Pitch Deck

PPTX — presentation

Investment Memo

DOCX — detailed memorandum

Financial Model

XLSX — 5-year projections

Get Started with AI

Prerequisites: Complete the DUAL Quick Start Guide to set up your environment and API keys before building this concept.

# PharmChain Token Deep-Dive

You are building the token system for PharmChain on DUAL Network.

## Context
- **Concept**: PharmChain
- **Alias**: Manufacturer-to-Dispenser Product Family Custody Ledger
- **Category**: Refined Concept
- **Viability**: 9.7/10

## Your Task
1. Review the investment memo and financial model
2. Design the immutable→mutable→compliance token schema
3. Map the user journey (6 steps with NAMED actors)
4. For each step, list which token fields mutate
5. Identify the 4 database comparison trade-offs
6. Define state machine with business event triggers

## Output
Return complete JSON with all sections filled from memo data:
- token_schema (15+ fields, domain-specific)
- journey_steps (with real actor names)
- db_comparison (4 rows comparing approaches)
- competitors (3-4 with weaknesses)
- projections (Y1-Y5 ARR and customer count)
- risks (3-4 with category, detail, mitigation)

## Key Principles
- Token = mutable business logic + immutable compliance trail
- Every field must serve a purpose (no generic metadata)
- Multi-party transparency without breaking privacy
- Standards-based, portable across platforms

Start here.